Abstract

Bile acids are increasingly being appreciated as complex metabolic integrators and signalling factors and not just as lipid solubilizers and simple regulators of bile-acid homeostasis. It is therefore not surprising that a number of bile-acid-activated signalling pathways have become attractive therapeutic targets for metabolic disorders. Here, we review how the signalling functions of bile acids can be exploited in the development of drugs for obesity, type 2 diabetes, hypertriglyceridaemia and atherosclerosis, as well as other associated chronic diseases such as non-alcoholic steatohepatitis.

Author affiliations

1. Institute of Genetics and Molecular and Cellular Biology, 1 Rue Laurent Fries, 67404 Illkirch, France.
2. Department of Chemistry and Pharmaceutical Technology, University of Perugia, 06123 Perugia, Italy.
3. Intercept Pharmaceuticals, 18 Desbrosses Street, New York, New York 10013, USA.
4. Mouse Clinical Institute, 1 Rue Laurent Fries, 67404 Illkirch, France.
5. Swiss Federal Institute of Technology, CH 1015 Lausanne, Switzerland.

Correspondence to: Kristina Schoonjans^1,5 Email: kristina.schoonjans@epfl.ch

Correspondence to: Johan Auwerx^1,4,5 Email: johan.auwerx@epfl.ch

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.